Full course description
Metrex has recently performed an efficacy study on CaviWipes against the SARS-CoV (SARS-associated Human Coronavirus) in a third-party test lab. According to the study report, the study results passed the Viricidal Hard Surface Efficacy Test by exceeding a 3-log/ 99.9% reduction of the virus. However, this study result has not yet been reviewed or approved by the US EPA. CaviWipes does not have an Emerging Viral Pathogen claim, nor a labelling claim against Human Coronavirus.